Subscribe

Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

HKD1.00 +0.01 (+1.01%)
HK HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address CNT Tower
Wan Chai, HK
CEO Liwei Yu
Website dawnrays.com
IPO 2003-07-11
ISIN KYG2687M1006

Explore sections of this company profile

Description

Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD1.00 +0.01 (+1.01%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
113.9K
Beta
0.22
Float Shares
487.81M
Free Float %
32.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.94% -4.55% -7.08% -11.76% -16.00% -13.93% -13.93% -15.32% -43.85% -64.16% +153.01%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.00
DCF (Unlevered) 3.22 +222.0%
DCF (Levered) 3.21 +220.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.77
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +16.1% ★ Q4'25: +19.8% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -63.2% Q4'25: +53.3% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +12.4% Q4'25: +23.3% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +18.5% ★ Q4'25: +19.9% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +10.2% ★ Q4'25: +23.2% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -0.1% ★ Q4'25: +0.2% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.23× ★ Q4'25: 0.10× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.27) × ERP
WACC = 95% × Ke + 5% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 3.23 Current price: 1.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
914.97M
est: 781.44M (+17.1%)
783.80M
est: 754.36M (+3.9%)
985.00M
est: 1.24B (-20.9%)
824.35M
est: 1.04B (-20.8%)
882.48M
est: 1.23B (-28.3%)
948.94M
est: 1.11B (-14.8%)
950.01M
est: 1.17B (-18.7%)
1.02B
est: 1.77B (-42.2%)
1.17B
est: 1.45B (-19.9%)
1.28B
est: 1.63B (-21.7%)
1.23B
est: 1.23B (+0.0%)
1.23B
1.23B – 1.23B
+0.0% YoY
1.11B
1.11B – 1.11B
-9.4% YoY
1.17B
1.17B – 1.17B
+4.8% YoY
1.77B
1.77B – 1.77B
+51.7% YoY
1.45B
1.45B – 1.45B
-17.9% YoY
1.63B
1.63B – 1.63B
+12.3% YoY
EBITDA
227.98M
est: 289.46M (-21.2%)
308.15M
est: 169.86M (+81.4%)
432.83M
est: 280.18M (+54.5%)
386.27M
est: 385.56M (+0.2%)
418.36M
est: 455.78M (-8.2%)
430.56M
est: 359.78M (+19.7%)
341.59M
est: 432.58M (-21.0%)
395.71M
est: 656.13M (-39.7%)
433.89M
est: 538.63M (-19.4%)
505.19M
est: 604.74M (-16.5%)
343.66M
est: 429.42M (-20.0%)
429.42M
429.42M – 429.42M
+0.0% YoY
388.86M
388.86M – 388.86M
-9.4% YoY
407.55M
407.55M – 407.55M
+4.8% YoY
618.18M
618.18M – 618.18M
+51.7% YoY
507.48M
507.48M – 507.48M
-17.9% YoY
569.76M
569.76M – 569.76M
+12.3% YoY
EBIT
192.57M
est: 242.17M (-20.5%)
261.70M
est: 148.16M (+76.6%)
378.71M
est: 242.35M (+56.3%)
333.46M
est: 322.57M (+3.4%)
365.72M
est: 381.31M (-4.1%)
378.93M
est: 325.47M (+16.4%)
319.40M
est: 361.90M (-11.7%)
336.13M
est: 548.93M (-38.8%)
380.76M
est: 450.63M (-15.5%)
438.78M
est: 505.94M (-13.3%)
227.42M
est: 346.02M (-34.3%)
346.02M
346.02M – 346.02M
+0.0% YoY
313.35M
313.35M – 313.35M
-9.4% YoY
328.41M
328.41M – 328.41M
+4.8% YoY
498.13M
498.13M – 498.13M
+51.7% YoY
408.93M
408.93M – 408.93M
-17.9% YoY
459.11M
459.11M – 459.11M
+12.3% YoY
Net Income
153.10M
est: 121.67M (+25.8%)
205.15M
est: 117.78M (+74.2%)
302.20M
est: 189.98M (+59.1%)
265.92M
est: 289.25M (-8.1%)
292.98M
est: 271.18M (+8.0%)
303.96M
est: 256.06M (+18.7%)
255.43M
est: 274.87M (-7.1%)
268.13M
est: 437.33M (-38.7%)
358.18M
est: 422.28M (-15.2%)
358.06M
est: 538.89M (-33.6%)
213.97M
est: 288.31M (-25.8%)
288.31M
288.31M – 288.31M
+0.0% YoY
303.50M
303.50M – 303.50M
+5.3% YoY
279.92M
279.92M – 279.92M
-7.8% YoY
466.24M
466.24M – 466.24M
+66.6% YoY
464.18M
464.18M – 464.18M
-0.4% YoY
550.45M
550.45M – 550.45M
+18.6% YoY
SGA
174.36M
est: 160.60M (+8.6%)
160.42M
est: 133.32M (+20.3%)
169.41M
est: 147.60M (+14.8%)
163.52M
est: 213.93M (-23.6%)
170.58M
est: 252.88M (-32.5%)
190.04M
est: 148.17M (+28.3%)
181.90M
est: 240.01M (-24.2%)
163.80M
est: 364.05M (-55.0%)
226.44M
est: 298.86M (-24.2%)
264.79M
est: 335.53M (-21.1%)
244.27M
est: 262.37M (-6.9%)
262.37M
262.37M – 262.37M
+0.0% YoY
237.59M
237.59M – 237.59M
-9.4% YoY
249.01M
249.01M – 249.01M
+4.8% YoY
377.70M
377.70M – 377.70M
+51.7% YoY
310.06M
310.06M – 310.06M
-17.9% YoY
348.12M
348.12M – 348.12M
+12.3% YoY
EPS
0.10
est: 0.08 (+18.2%)
0.13
est: 0.10 (+25.8%)
0.19
est: 0.18 (+6.6%)
0.17
est: 0.19 (-11.5%)
0.18
est: 0.18 (0.0%)
0.19
est: 0.19 (+1.0%)
0.16
est: 0.18 (-12.3%)
0.17
est: 0.29 (-41.5%)
0.24
est: 0.28 (-14.4%)
0.24
est: 0.36 (-32.9%)
0.14
est: 0.19 (-27.0%)
0.19
0.19 – 0.19
+0.0% YoY
0.20
0.20 – 0.20
+5.3% YoY
0.19
0.19 – 0.19
-7.8% YoY
0.31
0.31 – 0.31
+66.6% YoY
0.31
0.31 – 0.31
-0.4% YoY
0.37
0.37 – 0.37
+18.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-28 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-27 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-26 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-22 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-21 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-20 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-19 A+ 4/5 5/5 3/5 5/5 3/5 3/5 5/5
2026-05-18 A+ 4/5 5/5 3/5 5/5 3/5 3/5 5/5
2026-05-15 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-14 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-13 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-12 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-11 A 4/5 5/5 3/5 4/5 3/5 3/5 5/5
2026-05-08 A+ 4/5 5/5 3/5 4/5 3/5 4/5 5/5
2026-05-07 A+ 4/5 5/5 3/5 4/5 3/5 4/5 5/5
2026-05-06 A+ 4/5 5/5 3/5 4/5 3/5 4/5 5/5
2026-05-04 A+ 4/5 5/5 3/5 4/5 3/5 4/5 5/5
2026-04-30 A+ 4/5 5/5 3/5 4/5 3/5 4/5 5/5
2026-04-29 A+ 5/5 5/5 3/5 5/5 3/5 4/5 5/5
2026-04-27 A+ 5/5 5/5 3/5 5/5 3/5 4/5 5/5
2026-04-24 A+ 4/5 5/5 3/5 5/5 2/5 4/5 5/5
2026-04-23 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5
2026-04-22 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5
2026-04-21 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5
2026-04-20 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5
2026-04-17 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5
2026-04-16 A 4/5 5/5 3/5 5/5 2/5 3/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
259.30M
OE per share TTM
0.17
Owner's Yield
15.90%
Maintenance CapEx ratio
59.85%
Maint CapEx / Avg PPE
94.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
192.2K
Shares Outstanding
1.50B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Liwei Yu Chief Executive Officer 5M female
Kei Ling Li Co-Founder & Executive Chairman 1M female
Yung Lai Hung Co-Founder & Executive Director 791.6K male
Kit Ling Pang Company Secretary — female
Yi Jun Wu Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic